BEIJING, Sept. 25 (Xinhua) -- China's economic planner on Tuesday announced a rise in the ceiling retail price of domestically produced albumin prepared from human plasma (APHM) to 360 yuan per 10 grams, or 50 milliliters.
Calling it a temporary price hike taking effect from Sep. 28, the National Development and Reform Commission (NDRC) did not say how long the new price would remain in effect.
The move was designed to ease shortages of APMH in China and control its growing market prices, said the NDRC.
On Jan. 26, the NDRC lowered the ceiling price of the APHM from330 yuan to 259 yuan.
APHM is given to patients recovering from blood loss, such as that caused by major surgery, and is believed to be in short supply across the country.
The NDRC also announced the price of imported APHM would rise by up to five percent in a bid to encourage imports of the product.
To ensure supplies in remote inland provincial areas, the commission allowed the APHM price to rise by five percent in Qinghai and other eight provincial-level regions. (One U.S. dollarequals to 7.51 yuan)